Home / Stocks / Jupiter Life Line Hosp L
JLHL

Jupiter Life Line Hosp L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹281.2

Change

-8.4 (-2.9%)

Open

₹286.0

Prev. Close

₹289.6

Day High

₹291.35

Day Low

₹279.0

Volume Analysis

Traded

99,872

Delivered

47,583

Delivery %

47.64%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (22.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (33.1%)
  • •Strong 3-year revenue growth (18.9%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹301.05 ₹296.2 ₹288.7 ₹283.85 ₹276.35 ₹271.5 ₹264.0
Fibonacci ₹296.2 ₹291.48 ₹288.57 ₹283.85 ₹279.13 ₹276.22 ₹271.5
Camarilla ₹284.6 ₹283.46 ₹282.33 ₹283.85 ₹280.07 ₹278.94 ₹277.8

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-79.88%

1 Week

-1.95%

1 Month

+14.1%

3 Months

-9.22%

6 Months

-79.27%

1 Year

-80.88%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹26.33

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

21.52%

Net margin 11.54% × asset turnover 0.74x × equity multiplier 2.52x

Company Overview

Sector

Healthcare

Market Cap

₹9,507 Cr

P/E (TTM)

50.0

ROE

13.1%

Book Value

₹49.7

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Jupiter Life Line Hosp L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 63/100. The strongest factor is Growth (98/100), while Valuation (13/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%). Strong 3-year EPS growth (33.1%).

TopFund Score — Fundamentals Quality

63/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

94

Growth

98

Valuation

13

Cash Flow

70

Corporate Governance

61

Momentum

55

Institutional Ownership

71

Business Quality

68

Risk & Volatility

25

Liquidity

29

From Screener.in

  • +Company has delivered good profit growth of 143% CAGR over last 5 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Received TMC permission to add 40-50 beds at Thane Hospital; ₹25 crore project due in one year.

Company to attend JM Financial investor conference in Mumbai on 16 November 2026.

Audio link shared for Q2 and H1 FY27 analyst and investor conference call held October 26, 2026.

Intimation of Newspaper Publication for Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 263 273 291 289 335 333 337 353 394 365 388 411 456
Expenses + 202 211 228 223 257 256 257 275 301 282 299 332 350
Operating Profit 61 62 63 65 78 76 80 78 92 83 89 79 107
OPM % 23.0% 23.0% 22.0% 23.0% 23.0% 23.0% 24.0% 22.0% 23.0% 23.0% 23.0% 19.0% 23.0%
Other Income + 3 8 10 7 7 7 7 13 11 3 11 11 11
Interest 12 1 1 1 1 3 6 8 8 8 9 13 14
Depreciation 11 11 10 11 14 14 18 21 21 22 23 26 28
Profit before tax 41 58 62 60 70 67 63 62 74 57 68 51 75
Tax % 19.0% 25.0% 27.0% 26.0% 26.0% 22.0% 28.0% 29.0% 23.0% 25.0% 26.0% 26.0% 25.0%
Net Profit + 34 44 45 45 52 52 45 44 57 42 50 38 56
EPS in Rs 1 1 1 1 2 2 1 1 2 1 2 1 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 19 19 20 19 27 22 16 22 17 10 15 16 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 320 398 463 486 733 893 1,073 1,302 1,500 1,621
Expenses + 266 333 379 419 580 691 831 999 1,156 1,262
Operating Profit 54 65 84 67 153 201 242 303 343 359
OPM % 17.0% 16.0% 18.0% 14.0% 21.0% 23.0% 23.0% 23.0% 23.0% 22.0%
Other Income + 5 2 0 4 4 8 22 25 37 35
Interest 16 24 26 39 44 42 26 11 33 43
Depreciation 20 24 26 31 36 39 42 57 88 100
Profit before tax 24 20 33 2 77 129 195 261 260 250
Tax % -25.0% 8.0% 10.0% 248.0% 34.0% 43.0% 10.0% 26.0% 25.0% —
Net Profit + 30 18 30 -2 51 73 177 194 194 187
EPS in Rs 1 1 1 0 2 3 5 6 6 6
Dividend Payout % 8.0% 0.0% 0.0% 0.0% 0.0% 0.0% 4.0% 3.0% 3.0% —
Sales growth — 24 — 5 51 22 20 21 15 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 147 162 186 188 243 309 1,103 1,291 1,479 1,565
Borrowings + 210 252 272 426 495 469 0 393 584 669
Other Liabilities + 63 71 94 124 120 151 112 168 235 261
Total Liabilities 470 537 603 789 909 986 1,281 1,917 2,363 2,560
Fixed Assets + 379 431 435 630 684 720 718 978 1,384 1,439
CWIP 28 12 10 26 27 29 74 185 129 194
Investments 1 2 2 7 3 2 17 507 486 385
Other Assets + 63 92 156 126 195 235 473 247 364 543
Total Assets 470 537 603 789 909 986 1,281 1,917 2,363 2,560
Equity Capital 51 51 51 51 51 57 66 66 66 66

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 43 46 74 123 137 176 115 267 268
Cash from Investing Activity + -43 -58 -43 -295 -84 -94 -246 -497 -442
Cash from Financing Activity + 1 16 -32 184 32 -51 128 297 136
Net Cash Flow 1 3 -1 12 85 31 -3 66 -38
Free Cash Flow -4 -15 46 -118 46 100 29 -60 -234
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 100 92 106 198 95 97 68 109 97

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 40.91% → 40.91%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 41.19% 40.76% 39.18% 36.79% 33.31% 33.43% 33.51% 33.08% 33.17% 33.6% 33.2% 30.85%
Promoters 40.91% 40.91% 40.91% 40.91% 40.91% 40.91% 40.91% 40.91% 40.91% 40.91% 40.91% 40.91%
FII 3.96% 4.17% 6.06% 8.84% 10.04% 10.04% 9.77% 9.06% 8.48% 8.48% 9.37% 9.13%
DII 13.92% 14.16% 13.85% 13.46% 15.75% 15.64% 15.82% 16.97% 17.44% 17.01% 16.51% 19.13%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Jupiter Life Line Hosp L (this stock) 9,507 50.0 5.84 13.1%
Strides Pharma Sci Ltd 9,353 16.2 2.74 20.0%
Paras Healthcare Limited 9,284 129.0 — 13.0%
Aarti Pharmalabs Limited 9,212 35.4 4.08 8.59%
Blue Jet Healthcare Ltd 9,989 70.9 — 52.1%
Yatharth Hosp & Tra C S L 10,222 53.6 5.44 10.2%
Symbiotec Pharmalab Ltd 10,354 70.0 7.6 11.7%

Which Mutual Funds Hold Jupiter Life Line Hosp L?

Frequently Asked Questions about Jupiter Life Line Hosp L

Community Sentiment

What are other investors saying about Jupiter Life Line Hosp L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.